Maven Securities LTD Makes New Investment in Protara Therapeutics, Inc. $TARA

Maven Securities LTD bought a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 754,626 shares of the company’s stock, valued at approximately $4,022,000. Maven Securities LTD owned approximately 1.46% of Protara Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. UBS Group AG boosted its holdings in shares of Protara Therapeutics by 44.2% during the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after buying an additional 372,463 shares in the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of Protara Therapeutics by 8.1% during the 4th quarter. Oppenheimer & Co. Inc. now owns 223,767 shares of the company’s stock worth $1,193,000 after buying an additional 16,794 shares in the last quarter. Almanack Investment Partners LLC. boosted its holdings in shares of Protara Therapeutics by 76.2% during the 4th quarter. Almanack Investment Partners LLC. now owns 23,782 shares of the company’s stock worth $127,000 after buying an additional 10,288 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Protara Therapeutics by 9.0% during the 3rd quarter. GSA Capital Partners LLP now owns 101,488 shares of the company’s stock worth $441,000 after buying an additional 8,375 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Protara Therapeutics by 35.8% during the 3rd quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock worth $85,000 after buying an additional 5,154 shares in the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Insider Buying and Selling

In other Protara Therapeutics news, insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the transaction, the insider owned 95,961 shares in the company, valued at $504,754.86. This trade represents a 19.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is currently owned by corporate insiders.

Protara Therapeutics Stock Performance

Shares of TARA opened at $3.90 on Monday. The business has a 50-day moving average of $4.90 and a 200 day moving average of $5.56. Protara Therapeutics, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The firm has a market cap of $219.18 million, a P/E ratio of -2.91 and a beta of 1.45.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.05. As a group, research analysts predict that Protara Therapeutics, Inc. will post -1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Oppenheimer increased their price target on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. UBS Group restated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Protara Therapeutics in a report on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $26.25.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.